CMA Issues £70m Fines To Pfizer And Flynn Over Phenytoin
UK Regulator Finds Firms Abused Dominant Position To Overcharge NHS
After reassessing part of a UK case involving Pfizer and Flynn Pharma over pricing for phenytoin sodium capsules, the country’s competition regulator has reaffirmed that the companies abused their dominant positions to overcharge the NHS and has issued £70m in fines.
You may also be interested in...
A UK appeals court has provided detailed guidance on how the country’s Competition and Markets Authority should evaluate unfair pricing, as part of a ruling that upholds a previous decision to overturn CMA fines of almost £90m ($112m) imposed on Pfizer and marketing partner Flynn Pharma over pricing for phenytoin sodium capsules.
Fines totalling almost £90 million (US$120 million) imposed on Pfizer and its marketing partner Flynn Pharma over allegedly unfair UK pricing for phenytoin sodium capsules have been overturned by the country’s Competition Appeal Tribunal. Having invited written submissions, the Tribunal intends to remit the dispute for reconsideration by the UK’s Competition and Markets Authority (CMA).
Stada has begun work on a facility in Romania into which the German giant is investing more than €50m to bolster the European supply chain.